- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA panel votes down CTI product
An advisory committee to the FDA recommended Dec. 10 against the approval of an optical imaging technology being developed by Computerized Thermal Imaging (Portland, OR). The FDA's Radiological Devices Panel voted 4 to 3 that the FDA deny approval of the
An advisory committee to the FDA recommended Dec. 10 against the approval of an optical imaging technology being developed by Computerized Thermal Imaging (Portland, OR). The FDA's Radiological Devices Panel voted 4 to 3 that the FDA deny approval of the company's infrared breast imaging system. Panel members described the technology as promising but decided more clinical data were necessary for members to recommend approval. The FDA has yet to decide on the matter.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
